Lightnews — Scholar-powered news

Ajay Major, MD, MBA

@majorajay.bsky.social

550 followers 220 following 350 posts

Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky

Posts Media Videos Starter Packs

Pinned

Ajay Major, MD, MBA @majorajay.bsky.social · Dec 4

Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from #ASH24. 🧵 #ASHEducation #ASHKudos cc @ash-hematology.bsky.social

3 10

Ajay Major, MD, MBA @majorajay.bsky.social · 2d

CNS penetration of pola @bloodadvances.bsky.social
- 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively)
- pola detected in CSF of CNSL & systemic LBCL pts
Provocative but unclear about single-agent activity. #lymsm
ashpublications.org/bloodadvance...

1 2

Ajay Major, MD, MBA @majorajay.bsky.social · 9d

Happy ASH abstract notification day! Looking forward to all your posters and orals in just a few months. #ASH25 @ash.hematology.org

Ajay Major, MD, MBA @majorajay.bsky.social · Aug 24

Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our new JNCI manuscript highlights need for tailored screening guidelines. #medsky #oncsky #survonc academic.oup.com/jnci/advance...

1 8

Ajay Major, MD, MBA @majorajay.bsky.social · Aug 17

Survival after incidental vs symptomatic FL:
- 908 pts, 29% incidental
- incidental: more early stage & normal LDH
- no diff in EFS, lymphoma-specific survival, or OS between groups
We can answer the "what if this was picked up earlier" question! #lymsm
www.nature.com/articles/s41...

Ajay Major, MD, MBA @majorajay.bsky.social · Aug 8

Is this my brand now, ASH?! Very honored to receive this award! 🤣😂 #ASHCRTI @ash.hematology.org

Ajay Major, MD, MBA @majorajay.bsky.social · Aug 6

Dr. Susie Curtis: "Grants are like blood clots; you're more likely to get one if you've already had one." #medsky #ASHCRTI @ash.hematology.org

Ajay Major, MD, MBA @majorajay.bsky.social · Aug 5

Our CRTI group PROs and Poop! 💩 (intersection of patient-reported outcomes and fecal microbiome) #ASHCRTI cc @ash.hematology.org @biostatgirl.bsky.social

1 1 3

Ajay Major, MD, MBA @majorajay.bsky.social · Aug 3

Day 1 of @ash.hematology.org CRTI! Super excited to learn from all these phenomenal investigators and faculty this week. #medsky #ASHKudos

1 3

Ajay Major, MD, MBA @majorajay.bsky.social · Aug 2

Congratulations to Dr. Ogamba and this phenomenal group of investigators on execution of this large patient-reported outcomes study! And many thanks for the opportunity to contribute our PRO & financial toxicity methodologic expertise. #gyncsm #gynonc #medsky #oncsky

www.nature.com/articles/s41...

Factors associated with health-related quality of life and financial toxicity among gynecological cancer patients in Southern Nigeria - Scientific Reports

Scientific Reports - Factors associated with health-related quality of life and financial toxicity among gynecological cancer patients in Southern Nigeria

www.nature.com

Ajay Major, MD, MBA @majorajay.bsky.social · Jul 21

Also, significantly worse G3+ AEs with epco:
- 12% G3+ CRS epco, 2% glofi, 3 G5 CRS with epco (!!!)
- 3.2% G3+ ICANS epco, 1% glofi, 1 G5 ICANS with epco
#lymsm #tcellrx

Ajay Major, MD, MBA @majorajay.bsky.social · Jul 21

Bispecifics in R/R LBCL @bloodjournals.hematology.org:
- 245 pts, 64% epcor, 60% CAR
- mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi
- mOS 7.8 mos overall (in MV model, glofi = better OS)
- worse PFS/OS if trial ineligible & w/i 90 d of CAR
Outcomes not great. #lymsm
ashpublications.org/blood/articl...

1 1

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 27

No more REMS for FDA-approved CAR-T products! Also, labeling updated for only 2 weeks in proximity to CAR center and 2 weeks no driving. #lymsm #tcellrx #mmsm www.fda.gov/vaccines-blo...

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 20

TP53mut 1L CLL zanu SEQUOIA #18ICML
- 111 pts, med age 71
- 5-yr PFS 72%, OS 85%
- 5% G5 AEs (not specified)
- 33% G3+ infx
Great PFS for TP53mut disease. My preferred option for patients. #lymsm

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 20

5-yr f/u CLL13/GAIA #18ICML
- best PFS with GIV (5-yr 81%)
- uIGHV with worse PFS with GV (5-yr 59%) vs GIV (76%)
- no diff in OS between all 4 arms
- more infx & cardiac AEs with GIV vs GV
With uIGHV may consider acala/ven/obinu per AMPLIFY (or just good ol' GV). #18ICML #lymsm

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 19

inMIND tafa-R2 RCT in R/R FL #18ICML
- 548 pts, 50% FLIPI 3-5, 32% POD24
- mPFS 22 mos (v 14 mos) with tafa
- benefit seen with tafa in POD24 subgroup
- superior TTNT, no diff OS, more deaths pbo arm
- no HT events with tafa, multiple seen w/ pbo
Now FDA approved in FL! #lymsm

1 1

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 19

Mosun in 1L FL #18ICML
- 76 pts, ORR 95%, CR 82%
- 1-yr PFS 89%, OS 99%
- CRS mostly G1, 3% req'd hospitalization for infx
- 1 death d/t COVID during tx
Looking forward to longer f/u. #lymsm #tcellrx

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 19

Ph3 ibru-R v placebo-R in 1L FL #18ICML
- 445 pts, med age 75
- PFS superior with ibr (altho not that much better vs R mono), no OS difference (although ibru OS curve worse!)
- 15% G5 AEs (!!!) in ibru arm
Way too toxic (and indefinite tx) in an indolent disease. #lymsm

1 2

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 19

Outcomes Stage IA NLPHL: superior PFS (not OS) for RT after complete resection (vs observation). For unresected patients, best PFS with RT & RT+ABVD, no diff OS. No diff in transformation events. More numerical SPMs after RT. #lymsm #18ICML

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 19

EBV+ pts in S1826 had much better PFS with nivo-AVD, although age & IPS differences between EBV+/- cohorts. Non-NS histologies also had much better PFS with nivo. #18ICML #lymsm

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 19

One of the longest follow-up studies I've seen in DLBCL. Excess mortality from infection remains higher than general population for greater than 10 years. AML/MDS highest 1-4 yrs, lung & GI cancers 5-25 yrs. Cardiac deaths have fallen over time. #18ICML #lymsm

Reposted by Ajay Major, MD, MBA

Graham Collins @graham74gc.bsky.social · Jun 18

Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL.
• operationally deliverable with ctDNA turnaround median 9d
• low rate PET+ and ctDNA+ at interim
• assessing whether acala addition benefits those with Myd88 &/or CD79b mutns
SAKK38/19 trial #ICML18

2 4

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 18

PROs from BRUIN-321 pirto vs idelaR/BR R/R CLL #18ICML
- pirto: better improvements in CLL-related sx, physical function, fatigue, all clinically significant
- 83% PRO completion pirto at week 25, only 59% other arm
Grain of salt given PRO dropout, but well reported. #lymsm

1 1

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 18

Accelerated ven ramp-up in CLL #18ICML
- 40 pts, nearly all +obinu, most low TLS risk
- 5-day daily escalation to 400 mg inpatient
- only one high risk pt had lab TLS
Obinu debulking before ven definitely helps. Maybe less time toxicity vs weekly ramp-up visits? #lymsm

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 18

We stan bridging RT before CAR! #18ICML
- 116 pts with comprehensive RT to all PET avid sites
- higher RT dose = less post-CAR G3+ CRS
- higher LDH after RT = more G3+ CRS/ICANS
Who else is using multisite bridging RT before CAR? #lymsm #tcellrx

Ajay Major, MD, MBA @majorajay.bsky.social · Jun 18

>1500 trial & @cibmtr.bsky.social pts who received liso-cel:
- 96-97% of CRS events were before D+15
- 88-95% ICANS before D+15
- no G5 CRS/ICANS after D+15
Do we really need a full 30 days of monitoring after liso-cel? #lymsm #tcellrx #18ICML